drugset
drugset / Trial / NCT02901275

Enhancing Medication-based Analgesia in Humans

NCT02901275 ↗

Phase 2 Completed 29 enrolled Johns Hopkins University
NaSingle-groupTriple-blindBasic science

Summary

This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (Dilaudid).

Timeline

Start
2016-12
Primary completion
2020-03-23
Completion
2020-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 2.5 mg Oral
Subject Dronabinol Other / unclassified 5 mg Oral
Subject Dronabinol Other / unclassified 10 mg Oral
Subject Hydromorphone Other / unclassified 4 mg Oral

Indications

No indication recorded.